Clinical Trial

Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 6, 2023 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
Clinical trials, with a particular focus on recurrent ovarian cancer, play a crucial role in assessing the safety and efficacy of novel treatments for this condition. These trials serve as essential tools to determine whether new medications outperform traditional therapies, providing substantial evidence to support their widespread adoption. By actively participating in recurrent ovarian cancer observational study serves pivotal role in expanding the boundaries of medical knowledge and advancing the quality of care provided to those enduring the same condition.
Trial Details
NCT Number NCT06070285
Lead Sponsor Power Life Sciences Inc.
Conditions Recurrent Ovarian Cancer
Enrollment 500 participants
Start Date 2024-10
Primary Completion 2025-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2023-10-06